Provista Diagnostics has appointed Urial Kusiatin as CFO, Kelly Gordon as vice president of research and development, Doug Bradley as vice president of global marketing, and Wendy Morray as senior director of reimbursement.
Kusiatin started working with Provista as a consultant in 2013, then formally joined the company as its senior vice president of finance in 2015. He began his career at Deloitte and has since overseen strategy development, operational execution, and financial management for numerous companies in the life sciences industry.
Gordon joined Provista in 2015 as director of clinical development. Prior to Provista, she served as the CDx regulatory affairs manager for Roche Tissue Diagnostics.
Bradley joins Provista from Caris Life Sciences, where he served as vice president of marketing. Prior to Caris, he served as executive vice president of global marketing at Agendia.
Morray joins Provista from Prometheus Laboratories, where she served as the director of coding and reimbursement. Prior to Prometheus, she spent more than 35 years managing coverage and reimbursement strategy for various laboratories.